Immunotherapy for Neuro-oncology.
Brain metastases
Cell therapy
Cell vaccines
Checkpoint inhibitors
GBM immune microenvironment
Glioblastoma
Immunosuppressive macrophages
Immunotherapy combinations
Oncolytic viral therapies
Peptide vaccines
Tumor mutational load
Tumor-infiltrating lymphocytes
Journal
Advances in experimental medicine and biology
ISSN: 0065-2598
Titre abrégé: Adv Exp Med Biol
Pays: United States
ID NLM: 0121103
Informations de publication
Date de publication:
2021
2021
Historique:
entrez:
1
1
2022
pubmed:
2
1
2022
medline:
5
1
2022
Statut:
ppublish
Résumé
Immunotherapy has changed the landscape of treatment of many solid and hematological malignancies and is at the forefront of cancer breakthroughs. Several circumstances unique to the central nervous system (CNS) such as limited space for an inflammatory response, difficulties with repeated sampling, corticosteroid use for management of cerebral edema, and immunosuppressive mechanisms within the tumor and brain parenchyma have posed challenges in clinical development of immunotherapy for intracranial tumors. Nonetheless, the success of immunotherapy in brain metastases (BMs) from solid cancers such as melanoma and non-small cell lung cancer (NSCLC) proves that the CNS is not an immune-privileged organ and is capable of initiating and regulating immune responses that lead to tumor control. However, the development of immunotherapeutics for the most malignant primary brain tumor, glioblastoma (GBM), has been challenging due to systemic and profound tumor-mediated immunosuppression unique to GBM, intratumoral and intertumoral heterogeneity, and lack of stably expressed clonal antigens. Here, we review recent advances in the field of immunotherapy for neuro-oncology with a focus on BM, GBM, and rare CNS cancers.
Identifiants
pubmed: 34972967
doi: 10.1007/978-3-030-79308-1_7
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
233-258Informations de copyright
© 2021. The Author(s), under exclusive license to Springer Nature Switzerland AG.
Références
Medawar, P. B. (1948). Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. British Journal of Experimental Pathology, 29(1), 58–69.
pubmed: 18865105
pmcid: 2073079
Woodroofe, M. N., Bellamy, A. S., Feldmann, M., Davison, A. N., & Cuzner, M. L. (1986). Immunocytochemical characterisation of the immune reaction in the central nervous system in multiple sclerosis. Possible role for microglia in lesion growth. Journal of the Neurological Sciences, 74(2–3), 135–152.
pubmed: 3488371
Louveau, A., Smirnov, I., Keyes, T. J., Eccles, J. D., Rouhani, S. J., Peske, J. D., et al. (2015). Structural and functional features of central nervous system lymphatic vessels. Nature, 523(7560), 337–341.
pubmed: 26030524
pmcid: 4506234
Venur, V. A., Karivedu, V., & Ahluwalia, M. S. (2018). Systemic therapy for brain metastases. Handbook of Clinical Neurology, 149, 137–153.
pubmed: 29307351
Ostrom, Q. T., Wright, C. H., & Barnholtz-Sloan, J. S. (2018). Brain metastases: epidemiology. Handbook of Clinical Neurology, 149, 27–42.
pubmed: 29307358
Achrol, A. S., Rennert, R. C., Anders, C., Soffietti, R., Ahluwalia, M. S., Nayak, L., et al. (2019). Brain metastases. Nature Reviews Disease Primers, 5(1), 5.
pubmed: 30655533
Tawbi, H. A., Forsyth, P. A., Algazi, A., Hamid, O., Hodi, F. S., Moschos, S. J., et al. (2018). Combined Nivolumab and Ipilimumab in melanoma metastatic to the brain. New England Journal of Medicine, 379(8), 722–730.
Goldberg, S. B., Gettinger, S. N., Mahajan, A., Chiang, A. C., Herbst, R. S., Sznol, M., et al. (2016). Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: Early analysis of a non-randomised, open-label, phase 2 trial. The Lancet Oncology, 17(7), 976–983.
pubmed: 27267608
pmcid: 5526047
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., et al. (2015). Pembrolizumab versus Ipilimumab in Advanced Melanoma. The New England Journal of Medicine, 372(26), 2521–2532.
pubmed: 25891173
Hargadon, K. M., Johnson, C. E., & Williams, C. J. (2018). Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. International Immunopharmacology, 62, 29–39.
pubmed: 29990692
Callahan, M. K., Wolchok, J. D., & Allison, J. P. (2010). Anti-CTLA-4 antibody therapy: Immune monitoring during clinical development of a novel immunotherapy. Seminars in Oncology, 37(5), 473–484.
pubmed: 21074063
pmcid: 3008567
Korn, E. L., Liu, P. Y., Lee, S. J., Chapman, J. A., Niedzwiecki, D., Suman, V. J., et al. (2008). Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. Journal of Clinical Oncology, 26(4), 527–534.
pubmed: 18235113
Callahan, M. K., Kluger, H., Postow, M. A., Segal, N. H., Lesokhin, A., Atkins, M. B., et al. (2018). Nivolumab plus Ipilimumab in patients with advanced melanoma: Updated survival, response, and safety data in a phase I dose-escalation study. Journal of Clinical Oncology, 36(4), 391–398.
pubmed: 29040030
Chukwueke, U., Batchelor, T., & Brastianos, P. (2016). Management of brain metastases in patients with melanoma. Journal of Oncology Practice, 12(6), 536–542.
pubmed: 27288470
Davies, M. A., Liu, P., McIntyre, S., Kim, K. B., Papadopoulos, N., Hwu, W. J., et al. (2011). Prognostic factors for survival in melanoma patients with brain metastases. Cancer, 117(8), 1687–1696.
pubmed: 20960525
Sloan, A. E., Nock, C. J., & Einstein, D. B. (2009). Diagnosis and treatment of melanoma brain metastasis: A literature review. Cancer Control, 16(3), 248–255.
pubmed: 19556965
Di Giacomo, A. M., Ascierto, P. A., Pilla, L., Santinami, M., Ferrucci, P. F., Giannarelli, D., et al. (2012). Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): An open-label, single-arm phase 2 trial. The Lancet Oncology, 13(9), 879–886.
pubmed: 22894884
Di Giacomo, A. M., Ascierto, P. A., Queirolo, P., Pilla, L., Ridolfi, R., Santinami, M., et al. (2015). Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study. Annals of Oncology, 26(4), 798–803.
pubmed: 25538176
Margolin, K., Ernstoff, M. S., Hamid, O., Lawrence, D., McDermott, D., Puzanov, I., et al. (2012). Ipilimumab in patients with melanoma and brain metastases: An open-label, phase 2 trial. The Lancet Oncology, 13(5), 459–465.
pubmed: 22456429
Kluger, H. M., Chiang, V., Mahajan, A., Zito, C. R., Sznol, M., Tran, T., et al. (2019). Long-term survival of patients with melanoma with active brain metastases treated with pembrolizumab on a phase II trial. Journal of Clinical Oncology, 37(1), 52–60.
pubmed: 30407895
Goldberg, S. B., Schalper, K. A., Gettinger, S. N., Mahajan, A., Herbst, R. S., Chiang, A. C., et al. (2020). Pembrolizumab for management of patients with NSCLC and brain metastases: Long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. The Lancet Oncology, 21(5), 655–663.
pubmed: 32251621
pmcid: 7380514
Borghaei, H., Pluzanski, A., Caro, R. B., Provencio, M., Burgers, S., Carcereny, E., et al. (2020). Abstract CT221: Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment for patients with advanced non-small cell lung cancer (NSCLC) with brain metastases: Results from CheckMate 227. Cancer Research, 80(16 Supplement), CT221-CT.
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J., et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England Journal of Medicine, 352(10), 987–996.
pubmed: 15758009
Sanai, N., & Berger, M. S. (2008). Glioma extent of resection and its impact on patient outcome. Neurosurgery, 62(4), 753–764; discussion 264–6.
pubmed: 18496181
Reardon, D. A., Gokhale, P. C., Klein, S. R., Ligon, K. L., Rodig, S. J., Ramkissoon, S. H., et al. (2016). Glioblastoma eradication following immune checkpoint blockade in an orthotopic, immunocompetent model. Cancer Immunology Research, 4(2), 124–135.
pubmed: 26546453
Fecci, P. E., Ochiai, H., Mitchell, D. A., Grossi, P. M., Sweeney, A. E., Archer, G. E., et al. (2007). Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clinical Cancer Research, 13(7), 2158–2167.
pubmed: 17404100
Reardon, D. A., Brandes, A. A., Omuro, A., Mulholland, P., Lim, M., Wick, A., et al. (2020). Effect of Nivolumab vs Bevacizumab in patients with recurrent glioblastoma: The CheckMate 143 phase 3 randomized clinical trial. JAMA Oncology, 6(7), 1003–1010.
pubmed: 32437507
Rosa K. Nivolumab Plus Temozolomide/Radiotherapy Misses OS End Point in Glioblastoma Multiforme 2020. Available from: https://www.onclive.com/view/nivolumab-plus-temozolomide-radiotherapy-misses-os-end-point-in-glioblastoma-multiforme
Bristol-Myers Squibb. Bristol-Myers Squibb Announces Phase 3 CheckMate -498 Study Did Not Meet Primary Endpoint of Overall Survival with Opdivo (nivolumab) Plus Radiation in Patients with Newly Diagnosed MGMT-Unmethylated Glioblastoma Multiforme 2019, May 9. Available from: https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-announces-phase-3-checkmate-498-study-did
Genoud, V., Marinari, E., Nikolaev, S. I., Castle, J. C., Bukur, V., Dietrich, P. Y., et al. (2018). Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models. Oncoimmunology, 7(12), e1501137.
pubmed: 30524896
pmcid: 6279422
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., et al. (2013). Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature, 499(7457), 214–218.
pubmed: 23770567
pmcid: 3919509
Yeung, J. T., Hamilton, R. L., Ohnishi, K., Ikeura, M., Potter, D. M., Nikiforova, M. N., et al. (2013). LOH in the HLA class I region at 6p21 is associated with shorter survival in newly diagnosed adult glioblastoma. Clinical Cancer Research, 19(7), 1816–1826.
pubmed: 23401227
pmcid: 3618546
Parsa, A. T., Waldron, J. S., Panner, A., Crane, C. A., Parney, I. F., Barry, J. J., et al. (2007). Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nature Medicine, 13(1), 84–88.
pubmed: 17159987
Wainwright, D. A., Chang, A. L., Dey, M., Balyasnikova, I. V., Kim, C. K., Tobias, A., et al. (2014). Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clinical Cancer Research, 20(20), 5290–5301.
pubmed: 24691018
pmcid: 4182350
Chang, N., Ahn, S. H., Kong, D. S., Lee, H. W., & Nam, D. H. (2017). The role of STAT3 in glioblastoma progression through dual influences on tumor cells and the immune microenvironment. Molecular and Cellular Endocrinology, 451, 53–65.
pubmed: 28089821
Ceccarelli, M., Barthel, F. P., Malta, T. M., Sabedot, T. S., Salama, S. R., Murray, B. A., et al. (2016). Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell, 164(3), 550–563.
pubmed: 26824661
pmcid: 4754110
de Groot, J., Penas-Prado, M., Alfaro-Munoz, K., Hunter, K., Pei, B. L., O’Brien, B., et al. (2020). Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro-Oncology, 22(4), 539–549.
pubmed: 31755915
Heimberger, A. B., Sun, W., Hussain, S. F., Dey, M., Crutcher, L., Aldape, K., et al. (2008). Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: Case study. Neuro-Oncology, 10(1), 98–103.
pubmed: 18079360
pmcid: 2600844
Schartner, J. M., Hagar, A. R., Van Handel, M., Zhang, L., Nadkarni, N., & Badie, B. (2005). Impaired capacity for upregulation of MHC class II in tumor-associated microglia. Glia, 51(4), 279–285.
pubmed: 15818597
Stevens, A., Kloter, I., & Roggendorf, W. (1988). Inflammatory infiltrates and natural killer cell presence in human brain tumors. Cancer, 61(4), 738–743.
pubmed: 3338036
Didenko, V. V., Ngo, H. N., Minchew, C., & Baskin, D. S. (2002). Apoptosis of T lymphocytes invading glioblastomas multiforme: A possible tumor defense mechanism. Journal of Neurosurgery, 96(3), 580–584.
pubmed: 11883844
pmcid: 1853267
Wischhusen, J., Friese, M. A., Mittelbronn, M., Meyermann, R., & Weller, M. (2005). HLA-E protects glioma cells from NKG2D-mediated immune responses in vitro: Implications for immune escape in vivo. Journal of Neuropathology and Experimental Neurology, 64(6), 523–528.
pubmed: 15977644
Wiendl, H., Mitsdoerffer, M., Hofmeister, V., Wischhusen, J., Bornemann, A., Meyermann, R., et al. (2002). A functional role of HLA-G expression in human gliomas: An alternative strategy of immune escape. Journal of Immunology, 168(9), 4772–4780.
Huettner, C., Czub, S., Kerkau, S., Roggendorf, W., & Tonn, J. C. (1997). Interleukin 10 is expressed in human gliomas in vivo and increases glioma cell proliferation and motility in vitro. Anticancer Research, 17(5A), 3217–3224.
pubmed: 9413151
Dix, A. R., Brooks, W. H., Roszman, T. L., & Morford, L. A. (1999). Immune defects observed in patients with primary malignant brain tumors. Journal of Neuroimmunology, 100(1–2), 216–232.
pubmed: 10695732
Grossman, S. A., Ye, X., Lesser, G., Sloan, A., Carraway, H., Desideri, S., et al. (2011). Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clinical Cancer Research, 17(16), 5473–5480.
pubmed: 21737504
pmcid: 3156964
Chongsathidkiet, P., Jackson, C., Koyama, S., Loebel, F., Cui, X., Farber, S. H., et al. (2018). Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nature Medicine, 24(9), 1459–1468.
pubmed: 30104766
pmcid: 6129206
Gustafson, M. P., Lin, Y., New, K. C., Bulur, P. A., O’Neill, B. P., Gastineau, D. A., et al. (2010). Systemic immune suppression in glioblastoma: The interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone. Neuro-Oncology, 12(7), 631–644.
pubmed: 20179016
pmcid: 2940665
Bloch, O., Crane, C. A., Kaur, R., Safaee, M., Rutkowski, M. J., & Parsa, A. T. (2013). Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clinical Cancer Research, 19(12), 3165–3175.
pubmed: 23613317
pmcid: 3742575
Iorgulescu, J. B., Gokhale, P. C., Speranza, M. C., Eschle, B. K., Poitras, M. J., Wilkens, M. K., et al. (2021). Concurrent dexamethasone limits the clinical benefit of immune checkpoint blockade in glioblastoma. Clinical Cancer Research, 27(1), 276–287.
pubmed: 33239433
Bouffet, E., Larouche, V., Campbell, B. B., Merico, D., de Borja, R., Aronson, M., et al. (2016). Immune checkpoint inhibition for Hypermutant glioblastoma Multiforme resulting from germline Biallelic mismatch repair deficiency. Journal of Clinical Oncology, 34(19), 2206–2211.
pubmed: 27001570
Johanns, T. M., Miller, C. A., Dorward, I. G., Tsien, C., Chang, E., Perry, A., et al. (2016). Immunogenomics of Hypermutated glioblastoma: A patient with germline POLE deficiency treated with checkpoint blockade immunotherapy. Cancer Discovery, 6(11), 1230–1236.
pubmed: 27683556
pmcid: 5140283
Viale, G., Trapani, D., & Curigliano, G. (2017). Mismatch repair deficiency as a predictive biomarker for immunotherapy efficacy. BioMed Research International, 2017, 4719194.
pubmed: 28770222
pmcid: 5523547
Kamiya-Matsuoka, C., Metrus, N. R., Shaw, K. R., Penas-Prado, M., Weathers, S.-P. S., Loghin, M. E., et al. (2018). The natural course of hypermutator gliomas. Journal of Clinical Oncology, 36(15_suppl), 2014-.
Omuro, A., Vlahovic, G., Lim, M., Sahebjam, S., Baehring, J., Cloughesy, T., et al. (2018). Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: Results from exploratory phase I cohorts of CheckMate 143. Neuro-Oncology, 20(5), 674–686.
pubmed: 29106665
Lim, M., Omuro, A., Vlahovic, G., Reardon, D. A., Sahebjam, S., Cloughesy, T., et al. (2017). 325ONivolumab (nivo) in combination with radiotherapy (RT) ± temozolomide (TMZ): Updated safety results from CheckMate 143 in pts with methylated or unmethylated newly diagnosed glioblastoma (GBM). Annals of Oncology, 28(suppl_5), mdx366-mdx.
Nayak, L., Molinaro, A. M., Peters, K., Clarke, J. L., Jordan, J. T., de Groot, J., et al. (2021). Randomized phase II and biomarker study of pembrolizumab plus bevacizumab versus pembrolizumab alone for patients with recurrent glioblastoma. Clinical Cancer Research, 27(4), 1048–1057.
pubmed: 33199490
Cloughesy, T. F., Mochizuki, A. Y., Orpilla, J. R., Hugo, W., Lee, A. H., Davidson, T. B., et al. (2019). Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nature Medicine, 25(3), 477–486.
pubmed: 30742122
pmcid: 6408961
Schalper, K. A., Rodriguez-Ruiz, M. E., Diez-Valle, R., Lopez-Janeiro, A., Porciuncula, A., Idoate, M. A., et al. (2019). Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Nature Medicine, 25(3), 470–476.
pubmed: 30742120
Amaria, R. N., Reddy, S. M., Tawbi, H. A., Davies, M. A., Ross, M. I., Glitza, I. C., et al. (2018). Publisher correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nature Medicine, 24(12), 1942.
pubmed: 30361511
Blank, C. U., Rozeman, E. A., Fanchi, L. F., Sikorska, K., van de Wiel, B., Kvistborg, P., et al. (2018). Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nature Medicine, 24(11), 1655–1661.
pubmed: 30297911
Forde, P. M., Chaft, J. E., & Pardoll, D. M. (2018). Neoadjuvant PD-1 blockade in resectable lung cancer. The New England Journal of Medicine, 379(9), e14.
pubmed: 30157404
Larkin, J., Hodi, F. S., & Wolchok, J. D. (2015). Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. The New England Journal of Medicine, 373(13), 1270–1271.
pubmed: 26398076
Hodges, T. R., Ott, M., Xiu, J., Gatalica, Z., Swensen, J., Zhou, S., et al. (2017). Mutational burden, immune checkpoint expression, and mismatch repair in glioma: Implications for immune checkpoint immunotherapy. Neuro-Oncology, 19(8), 1047–1057.
pubmed: 28371827
pmcid: 5570198
McGranahan, T., Li, G., & Nagpal, S. (2017). History and current state of immunotherapy in glioma and brain metastasis. Therapeutic Advances in Medical Oncology, 9(5), 347–368.
pubmed: 28529551
pmcid: 5424864
Dunn, G. P., Fecci, P. E., & Curry, W. T. (2012). Cancer immunoediting in malignant glioma. Neurosurgery, 71(2), 201–222; discussion 22–3.
pubmed: 22353795
Nduom, E. K., Weller, M., & Heimberger, A. B. (2015). Immunosuppressive mechanisms in glioblastoma. Neuro-Oncology, 17(Suppl 7), vii9–vii14.
pubmed: 26516226
pmcid: 4625890
Wainwright, D. A., Sengupta, S., Han, Y., & Lesniak, M. S. (2011). Thymus-derived rather than tumor-induced regulatory T cells predominate in brain tumors. Neuro-Oncology, 13(12), 1308–1323.
pubmed: 21908444
pmcid: 3223094
Lampson, L. A. (2011). Monoclonal antibodies in neuro-oncology: Getting past the blood-brain barrier. MAbs, 3(2), 153–160.
pubmed: 21150307
pmcid: 3092616
Gerstner, E. R., & Fine, R. L. (2007). Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: Establishing a treatment paradigm. Journal of Clinical Oncology, 25(16), 2306–2312.
pubmed: 17538177
Ou, A., Yung, W. K. A., & Majd, N. (2020). Molecular mechanisms of treatment resistance in glioblastoma. International Journal of Molecular Sciences, 22(1).
Desai, R., Suryadevara, C. M., Batich, K. A., Farber, S. H., Sanchez-Perez, L., & Sampson, J. H. (2016). Emerging immunotherapies for glioblastoma. Expert Opinion on Emerging Drugs, 21(2), 133–145.
pubmed: 27223671
pmcid: 4915370
Heimberger, A. B., Suki, D., Yang, D., Shi, W., & Aldape, K. (2005). The natural history of EGFR and EGFRvIII in glioblastoma patients. Journal of Translational Medicine, 3, 38.
pubmed: 16236164
pmcid: 1298339
Weller, M., Butowski, N., Tran, D. D., Recht, L. D., Lim, M., Hirte, H., et al. (2017). Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): A randomised, double-blind, international phase 3 trial. The Lancet Oncology, 18(10), 1373–1385.
pubmed: 28844499
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., et al. (2009). IDH1 and IDH2 mutations in gliomas. The New England Journal of Medicine, 360(8), 765–773.
pubmed: 19228619
pmcid: 2820383
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C., Leary, R. J., Angenendt, P., et al. (2008). An integrated genomic analysis of human glioblastoma multiforme. Science, 321(5897), 1807–1812.
pubmed: 2820389
pmcid: 2820389
Schumacher, T., Bunse, L., Pusch, S., Sahm, F., Wiestler, B., Quandt, J., et al. (2014). A vaccine targeting mutant IDH1 induces antitumour immunity. Nature, 512(7514), 324–327.
pubmed: 25043048
Pellegatta, S., Valletta, L., Corbetta, C., Patane, M., Zucca, I., Riccardi Sirtori, F., et al. (2015). Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma. Acta Neuropathologica Communications, 3, 4.
pubmed: 25849072
pmcid: 4359524
Michael Platten, D. S., Bunse, L., Wick, A., Bunse, T., Riehl, D., Green, E., Sanghvi, K., Karapanagiotou-Schenkel, I., Harting, I., Sahm, F., Steinbach, J., Weyerbrock, A., Hense, J., Misch, M., Krex, D., Stevanovic, S., Tabatabai, G., von Deimling, A., Schmitt, M., & Wick, W. (2018). ATIM-33. NOA-16: A first-in-man multicenter phase I clinical trial of the German neurooncology working group evaluating a mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas. Neuro-Oncology, 20(6), vi8–vi9.
pmcid: 6216146
Rampling, R., Peoples, S., Mulholland, P. J., James, A., Al-Salihi, O., Twelves, C. J., et al. (2016). A cancer research UK first time in human phase I trial of IMA950 (novel multipeptide therapeutic vaccine) in patients with newly diagnosed glioblastoma. Clinical Cancer Research, 22(19), 4776–4785.
pubmed: 27225692
pmcid: 5026298
Migliorini, D., Dutoit, V., Allard, M., Hallez, N. G., Marinari, E., Widmer, V., et al. (2019). Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients. Neuro-Oncology.
Keskin, D. B., Anandappa, A. J., Sun, J., Tirosh, I., Mathewson, N. D., Li, S., et al. (2019). Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature, 565(7738), 234–239.
pubmed: 30568305
Baratta, M. G. (2019). Glioblastoma is ‘hot’ for personalized vaccines. Nature Reviews. Cancer, 19(3), 129.
pubmed: 30705432
Hilf, N., Kuttruff-Coqui, S., Frenzel, K., Bukur, V., Stevanovic, S., Gouttefangeas, C., et al. (2019). Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature, 565(7738), 240–245.
pubmed: 30568303
Graner, M. W., & Bigner, D. D. (2005). Chaperone proteins and brain tumors: Potential targets and possible therapeutics. Neuro-Oncology, 7(3), 260–278.
pubmed: 16053701
pmcid: 1871914
Ampie, L., Choy, W., Lamano, J. B., Fakurnejad, S., Bloch, O., & Parsa, A. T. (2015). Heat shock protein vaccines against glioblastoma: From bench to bedside. Journal of Neuro-Oncology, 123(3), 441–448.
pubmed: 26093618
pmcid: 4520407
Bloch, O., Crane, C. A., Fuks, Y., Kaur, R., Aghi, M. K., Berger, M. S., et al. (2014). Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: A phase II, single-arm trial. Neuro-Oncology, 16(2), 274–279.
pubmed: 24335700
Ahluwalia, M. S., Reardon, D. A., Abad, A. P., Curry, W. T., Wong, E. T., Belal, A., et al. (2019). SurVaxM with standard therapy in newly diagnosed glioblastoma: Phase II trial update. Journal of Clinical Oncology, 37(15_suppl), 2016-.
Ardon, H., Van Gool, S. W., Verschuere, T., Maes, W., Fieuws, S., Sciot, R., et al. (2012). Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: Results of the HGG-2006 phase I/II trial. Cancer Immunology, Immunotherapy, 61(11), 2033–2044.
pubmed: 22527250
Liau, L. M., Ashkan, K., Tran, D. D., Campian, J. L., Trusheim, J. E., Cobbs, C. S., et al. (2018). First results on survival from a large phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. Journal of Translational Medicine, 16(1), 142.
pubmed: 29843811
pmcid: 5975654
Liau, L. M., Black, K. L., Martin, N. A., Sykes, S. N., Bronstein, J. M., Jouben-Steele, L., et al. (2000). Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report. Neurosurgical Focus, 9(6), e8.
pubmed: 16817691
Jena, B., Dotti, G., & Cooper, L. J. (2010). Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood, 116(7), 1035–1044.
pubmed: 20439624
pmcid: 2938125
Maher, J. (2014). Clinical immunotherapy of B-cell malignancy using CD19-targeted CAR T-cells. Current Gene Therapy, 14(1), 35–43.
pubmed: 24365143
Knochelmann, H. M., Smith, A. S., Dwyer, C. J., Wyatt, M. M., Mehrotra, S., & Paulos, C. M. (2018). CAR T cells in solid tumors: Blueprints for building effective therapies. Frontiers in Immunology, 9, 1740.
pubmed: 30140266
pmcid: 6094980
Brown, C. E., Alizadeh, D., Starr, R., Weng, L., Wagner, J. R., Naranjo, A., et al. (2016). Regression of glioblastoma after chimeric antigen receptor T-cell therapy. The New England Journal of Medicine, 375(26), 2561–2569.
pubmed: 28029927
pmcid: 5390684
O’Rourke, D. M., Nasrallah, M. P., Desai, A., Melenhorst, J. J., Mansfield, K., Morrissette, J. J. D., et al. (2017). A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Science Translational Medicine, 9(399).
Ahmed, N., Salsman, V. S., Kew, Y., Shaffer, D., Powell, S., Zhang, Y. J., et al. (2010). HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clinical Cancer Research, 16(2), 474–485.
pubmed: 20068073
pmcid: 3682507
Ahmed, N., Brawley, V., Hegde, M., Bielamowicz, K., Kalra, M., Landi, D., et al. (2017). HER2-specific chimeric antigen receptor–modified virus-specific T cells for progressive glioblastoma: A phase 1 dose-escalation TrialHER2-specific CAR-modified virus-specific T cells for progressive GlioblastomaHER2-specific CAR-modified virus-specific T cells for progressive glioblastoma. JAMA Oncology, 3(8), 1094–1101.
pubmed: 28426845
pmcid: 5747970
Weathers, S. P., Penas-Prado, M., Pei, B. L., Ling, X., Kassab, C., Banerjee, P., et al. (2020). Glioblastoma-mediated immune dysfunction limits CMV-specific T cells and therapeutic responses: Results from a phase I/II trial. Clinical Cancer Research, 26(14), 3565–3577.
pubmed: 32299815
John, L. B., Devaud, C., Duong, C. P., Yong, C. S., Beavis, P. A., Haynes, N. M., et al. (2013). Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clinical Cancer Research, 19(20), 5636–5646.
pubmed: 23873688
Vivier, E., Raulet, D. H., Moretta, A., Caligiuri, M. A., Zitvogel, L., Lanier, L. L., et al. (2011). Innate or adaptive immunity? The example of natural killer cells. Science, 331(6013), 44–49.
pubmed: 21212348
pmcid: 3089969
Nayyar, G., Chu, Y., & Cairo, M. S. (2019). Overcoming resistance to natural killer cell based immunotherapies for solid tumors. Frontiers in Oncology, 9, 51.
pubmed: 30805309
pmcid: 6378304
Ishikawa, E., Tsuboi, K., Saijo, K., Harada, H., Takano, S., Nose, T., et al. (2004). Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Research, 24(3b), 1861–1871.
pubmed: 15274367
Majd, N., Rizk, M., Ericson, S., Grzegorzewski, K., Koppisetti, S., Zhu, J., et al. (2020). RTID-07. Human placental hematopoietic stem cell derived natural killer cells (CYNK-001) for treatment of recurrent glioblastoma. Neuro-Oncology, 22(Supplement_2), ii194–ii5.
Jiang, H., McCormick, F., Lang, F. F., Gomez-Manzano, C., & Fueyo, J. (2006). Oncolytic adenoviruses as antiglioma agents. Expert Review of Anticancer Therapy, 6(5), 697–708.
pubmed: 16759161
Jiang, H., & Fueyo, J. (2014). Healing after death: Antitumor immunity induced by oncolytic adenoviral therapy. Oncoimmunology, 3(7), e947872.
pubmed: 25954598
pmcid: 4355947
Desjardins, A., Gromeier, M., Herndon, J. E., 2nd, Beaubier, N., Bolognesi, D. P., Friedman, A. H., et al. (2018). Recurrent glioblastoma treated with recombinant poliovirus. The New England Journal of Medicine, 379(2), 150–161.
pubmed: 29943666
pmcid: 6065102
Cloughesy, T. F., Petrecca, K., Walbert, T., Butowski, N., Salacz, M., Perry, J., et al. (2020). Effect of vocimagene amiretrorepvec in combination with flucytosine vs standard of care on survival following tumor resection in patients with recurrent high-grade glioma: A randomized clinical trial. JAMA Oncology, 6(12), 1939–1946.
pubmed: 33119048
Lang, F. F., Conrad, C., Gomez-Manzano, C., Yung, W. K. A., Sawaya, R., Weinberg, J. S., et al. (2018). Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: Replication and immunotherapeutic effects in recurrent malignant glioma. Journal of Clinical Oncology, 36(14), 1419–1427.
pubmed: 29432077
pmcid: 6075856
Perez, O. D., Logg, C. R., Hiraoka, K., Diago, O., Burnett, R., Inagaki, A., et al. (2012). Design and selection of Toca 511 for clinical use: Modified retroviral replicating vector with improved stability and gene expression. Molecular Therapy, 20(9), 1689–1698.
pubmed: 22547150
pmcid: 3437576
Cloughesy, T. F., Landolfi, J., Vogelbaum, M. A., Ostertag, D., Elder, J. B., Bloomfield, S., et al. (2018). Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC. Neuro-Oncology, 20(10), 1383–1392.
pubmed: 29762717
pmcid: 6120351
Chiocca, E. A., Nassiri, F., Wang, J., Peruzzi, P., & Zadeh, G. (2019). Viral and other therapies for recurrent glioblastoma: Is a 24-month durable response unusual? Neuro-Oncology, 21(1), 14–25.
pubmed: 30346600
Harrison, R. A., Anderson, M. D., Cachia, D., Kamiya-Matsuoka, C., Weathers, S. S., O’Brien, B. J., et al. (2019). Clinical trial participation of patients with glioblastoma at The University of Texas MD Anderson Cancer Center. European Journal of Cancer, 112, 83–93.
pubmed: 30951926
Chiocca, E. A., Abbed, K. M., Tatter, S., Louis, D. N., Hochberg, F. H., Barker, F., et al. (2004). A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Molecular Therapy, 10(5), 958–966.
pubmed: 15509513
Prins, R. M., Soto, H., Konkankit, V., Odesa, S. K., Eskin, A., Yong, W. H., et al. (2011). Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clinical Cancer Research, 17(6), 1603–1615.
pubmed: 21135147
Yu, J. S., Liu, G., Ying, H., Yong, W. H., Black, K. L., & Wheeler, C. J. (2004). Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Research, 64(14), 4973–4979.
pubmed: 15256471
Yamanaka, R., Abe, T., Yajima, N., Tsuchiya, N., Homma, J., Kobayashi, T., et al. (2003). Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: Results of a clinical phase I/II trial. British Journal of Cancer, 89(7), 1172–1179.
pubmed: 14520441
pmcid: 2394324
Zhai, L., Lauing, K. L., Chang, A. L., Dey, M., Qian, J., Cheng, Y., et al. (2015). The role of IDO in brain tumor immunotherapy. Journal of Neuro-Oncology, 123(3), 395–403.
pubmed: 25519303
Fallarino, F., Grohmann, U., Vacca, C., Bianchi, R., Orabona, C., Spreca, A., et al. (2002). T cell apoptosis by tryptophan catabolism. Cell Death and Differentiation, 9(10), 1069–1077.
pubmed: 12232795
Han, J., Alvarez-Breckenridge, C. A., Wang, Q. E., & Yu, J. (2015). TGF-beta signaling and its targeting for glioma treatment. American Journal of Cancer Research, 5(3), 945–955.
pubmed: 26045979
pmcid: 4449428
Bogdahn, U., Hau, P., Stockhammer, G., Venkataramana, N. K., Mahapatra, A. K., Suri, A., et al. (2011). Targeted therapy for high-grade glioma with the TGF-beta2 inhibitor trabedersen: Results of a randomized and controlled phase IIb study. Neuro-Oncology, 13(1), 132–142.
pubmed: 20980335
den Hollander, M. W., Bensch, F., Glaudemans, A. W. J. M., Enting, R. H., Bunskoek, S., Munnink, T. H. O., et al. (2013). 89zr-GC1008 PET imaging and GC1008 treatment of recurrent glioma patients. Journal of Clinical Oncology, 31(15_suppl), 2050-.
Rodon, J., Carducci, M. A., Sepulveda-Sanchez, J. M., Azaro, A., Calvo, E., Seoane, J., et al. (2015). First-in-human dose study of the novel transforming growth factor-beta receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma. Clinical Cancer Research, 21(3), 553–560.
pubmed: 25424852
Roy, L. O., Poirier, M. B., & Fortin, D. (2018). Differential expression and clinical significance of transforming growth factor-beta isoforms in GBM tumors. International Journal of Molecular Sciences, 19(4).
Pyonteck, S. M., Akkari, L., Schuhmacher, A. J., Bowman, R. L., Sevenich, L., Quail, D. F., et al. (2013). CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nature Medicine, 19(10), 1264–1272.
pubmed: 24056773
pmcid: 3840724
Butowski, N., Colman, H., De Groot, J. F., Omuro, A. M., Nayak, L., Wen, P. Y., et al. (2016). Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: An Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro-Oncology, 18(4), 557–564.
pubmed: 26449250
Goldberg, M. V., & Drake, C. G. (2011). LAG-3 in cancer immunotherapy. Current Topics in Microbiology and Immunology, 344, 269–278.
pubmed: 21086108
pmcid: 4696019
Harris-Bookman, S., Mathios, D., Martin, A. M., Xia, Y., Kim, E., Xu, H., et al. (2018). Expression of LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal antibodies in glioblastoma. International Journal of Cancer, 143(12), 3201–3208.
pubmed: 30248181
pmcid: 7105259
Lim, M., Ye, X., Piotrowski, A. F., Desai, A. S., Ahluwalia, M. S., Walbert, T., et al. (2019). Updated phase I trial of anti-LAG-3 or anti-CD137 alone and in combination with anti-PD-1 in patients with recurrent GBM. Journal of Clinical Oncology, 37(15_suppl), 2017-.
Pollok, K. E., Kim, Y. J., Zhou, Z., Hurtado, J., Kim, K. K., Pickard, R. T., et al. (1993). Inducible T cell antigen 4-1BB. Analysis of expression and function. Journal of Immunology, 150(3), 771–781.
Pilie, P. G., Gay, C. M., Byers, L. A., O’Connor, M. J., & Yap, T. A. (2019). PARP inhibitors: Extending benefit beyond BRCA-mutant cancers. Clinical Cancer Research, 25(13), 3759–3771.
pubmed: 30760478
Majd, N., Yap, T. A., Yung, W. K. A., & de Groot, J. (2020). The promise of poly(ADP-ribose) polymerase (PARP) inhibitors in gliomas. Journal of Immunotherapy and Precision Oncology, 3(4), 157–164.
Majd, N. K., Yap, T. A., Koul, D., Balasubramaniyan, V., Li, X., Khan, S., et al. (2021). The promise of DNA damage response inhibitors for the treatment of glioblastoma. Neuro-oncology Advances, 3(1), vdab015.
pubmed: 33738447
pmcid: 7954093
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., et al. (2016). The 2016 World Health Organization classification of tumors of the central nervous system: A summary. Acta Neuropathologica, 131(6), 803–820.
pubmed: 27157931
Louis, D. N., Ellison, D. W., Brat, D. J., Aldape, K., Capper, D., Hawkins, C., et al. (2019). cIMPACT-NOW: A practical summary of diagnostic points from round 1 updates. Brain Pathology, 29(4), 469–472.
pubmed: 31038238
pmcid: 8028562
Ostrom, Q. T., Cioffi, G., Gittleman, H., Patil, N., Waite, K., Kruchko, C., et al. (2019). CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2012–2016. Neuro-Oncology, 21(Supplement_5), v1–v100.
pubmed: 31675094
pmcid: 6823730
Marabelle, A., Le, D. T., Ascierto, P. A., Di Giacomo, A. M., De Jesus-Acosta, A., Delord, J. P., et al. (2020). Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study. Journal of Clinical Oncology, 38(1), 1–10.
pubmed: 31682550
Naing, A., Meric-Bernstam, F., Stephen, B., Karp, D. D., Hajjar, J., Rodon Ahnert, J., et al. (2020). Phase 2 study of pembrolizumab in patients with advanced rare cancers. Journal for Immunotherapy of Cancer, 8(1), e000347.
pubmed: 32188704
pmcid: 7078933
Lloyd, R. V., Osamura, R. Y., Klöppel, G., & Rosai, J. (Eds.). (2017). WHO classification of tumours of endocrine organs (4th ed.). IARC Press.
Daly, A. F., Tichomirowa, M. A., & Beckers, A. (2009). The epidemiology and genetics of pituitary adenomas. Best Practice & Research. Clinical Endocrinology & Metabolism, 23(5), 543–554.
Lin, A. L., Jonsson, P., Tabar, V., Yang, T. J., Cuaron, J., Beal, K., et al. (2018). Marked response of a hypermutated ACTH-secreting pituitary carcinoma to Ipilimumab and Nivolumab. The Journal of Clinical Endocrinology & Metabolism, 103(10), 3925–3930.
Duhamel, C., Ilie, M. D., Salle, H., Nassouri, A. S., Gaillard, S., Deluche, E., et al. (2020). Immunotherapy in corticotroph and lactotroph aggressive tumors and carcinomas: Two case reports and a review of the literature. Journal of Personalized Medicine, 10(3).
Majd, N., Waguespack, S. G., Janku, F., Fu, S., Penas-Prado, M., Xu, M., et al. (2020). Efficacy of pembrolizumab in patients with pituitary carcinoma: Report of four cases from a phase II study. Journal for Immunotherapy of Cancer, 8(2).
Pajtler, K. W., Witt, H., Sill, M., Jones, D. T. W., Hovestadt, V., Kratochwil, F., et al. (2015). Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell, 27(5), 728–743.
pubmed: 25965575
pmcid: 4712639
Tapia Rico, G., Townsend, A., Price, T., & Patterson, K. (2020). Metastatic myxopapillary ependymoma treated with immunotherapy achieving durable response. BMJ Case Reports, 13(12), e236242.
pubmed: 33334744
Clark, V. E., Erson-Omay, E. Z., Serin, A., Yin, J., Cotney, J., Ozduman, K., et al. (2013). Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science, 339(6123), 1077–1080.
pubmed: 23348505
pmcid: 4808587
Han, S. J., Reis, G., Kohanbash, G., Shrivastav, S., Magill, S. T., Molinaro, A. M., et al. (2016). Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma. Journal of Neuro-Oncology, 130(3), 543–552.
pubmed: 27624915
pmcid: 5560602
Dunn, I. F., Du, Z., Touat, M., Sisti, M. B., Wen, P. Y., Umeton, R., et al. (2018). Mismatch repair deficiency in high-grade meningioma: A rare but recurrent event associated with dramatic immune activation and clinical response to PD-1 blockade. JCO Precision Oncology, 2018.
Campbell, B. B., Light, N., Fabrizio, D., Zatzman, M., Fuligni, F., de Borja, R., et al. (2017). Comprehensive analysis of hypermutation in human cancer. Cell, 171(5), 1042-56.e10.
Kabir, T. F., Kunos, C. A., Villano, J. L., & Chauhan, A. (2020). Immunotherapy for medulloblastoma: Current perspectives. Immunotargets and Therapy, 9, 57–77.
pubmed: 32368525
pmcid: 7182450